, Tracking Stock Market Picks
Enter Symbol:
Ariad Pharmaceuticals, Inc. (ARIA) [hlAlert]

Neutral ARIA
up 16.10 %

Ariad Pharmaceuticals, Inc. (ARIA) downgraded to Neutral by JP Morgan

Posted on: Friday,  Oct 18, 2013  10:25 AM ET by JP Morgan

JP Morgan rated Neutral Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) on 10/18/2013. Previously JP Morgan rated Overweight Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) on
11/09/2009., when the stock price was $2.36. Since then, Ariad Pharmaceuticals, Inc. has gained 16.10% as of 10/18/2013's recent price of $2.74.
If you would have followed the previous JP Morgan's recommendation on ARIA, you would have gained 16.1% of your investment in 1439 days.

Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology. The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.

JPMorgan is a leading financial services firm with one of the largest client franchises in the world. We partner with our clients to offer the most complete and innovative solutions in the industry to help them achieve their goals. For more than 200 years, we have taken a long-term approach to our clients and to the way we conduct business. Our firm has grown considerably in scale and scope, but our commitment to our core principle of doing "only first-class business... in a first-class way" has never been stronger.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/18/2013 10:25 AM Hold
as of 12/13/2013
1 Week   
1 Month   
3 Months down  -86.73 %
1 YTD down  -85.71 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/9/2009 9:25 AM Buy
11/28/2007 9:25 AM Hold

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy